Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIa, safety study of the active implantable (radiological) medical device 32P BioSilicon, administered intratumourally to patients with advanced, unresectable pancreatic cancer, in addition to standard IV [intravenous] gemcitabine chemotherapy

Next Previous
Trial Profile

A phase IIa, safety study of the active implantable (radiological) medical device 32P BioSilicon, administered intratumourally to patients with advanced, unresectable pancreatic cancer, in addition to standard IV [intravenous] gemcitabine chemotherapy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use

Most Recent Events

  • 27 Jul 2007 The expected completion date for this trial is now 1 Jun 2008.
  • 25 Nov 2006 New trial record.
  • 29 Jun 2006 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top